Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties

References

• Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 2001;22:1931–1937.
   PubMed Web of Science ®Google Scholar
• Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. 2014. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Reviews Clin Oncology. 11:282–298. doi:10.1038/nrclinonc.2014.51.
   PubMed Web of Science ®Google Scholar
• Cheung-Ong K, Giaever G, Nislow C. 2013. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 20:648–659. doi:10.1016/j.chembiol.2013.04.007.
   PubMedGoogle Scholar
• Tiwari M. 2012. Antimetabolites: established cancer therapy. J Cancer Res Ther. 8:510–519. doi:10.4103/0973-1482.106526.
   PubMed Web of Science ®Google Scholar
• Hagner N, Joerger M. 2010. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2:293–301. doi:10.2147/CMR.S10043.
   PubMedGoogle Scholar
• Shao J, Liu X, Zhu L, Yen Y. 2013. Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets. 17:1423–1437. doi:10.1517/14728222.2013.840293.
   PubMed Web of Science ®Google Scholar
• Delgado JL, Hsieh C-M, Chan N-L, Hiasa H. 2018. Topoisomerases as anticancer targets. Biochem J. 475:373–398. doi:10.1042/BCJ20160583.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Current Opinion Investigational Drugs (London, England: 2000). 2002;3:1512–1516.
   PubMedGoogle Scholar
• Nitiss JL. 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Reviews Canc. 9:338–350. doi:10.1038/nrc2607.
   PubMed Web of Science ®Google Scholar
• Collins I, Weber A, Levens D. 2001. Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol. 21:8437–8451. doi:10.1128/MCB.21.24.8437-8451.2001.
   PubMed Web of Science ®Google Scholar
• Pommier Y. 2013. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 8:82–95. doi:10.1021/cb300648v.
   PubMed Web of Science ®Google Scholar
• Doublie S, Zahn KE. 2014. Structural insights into eukaryotic DNA replication. Front Microbiol. 5:444. doi:10.3389/fmicb.2014.00547.
   PubMed Web of Science ®Google Scholar
• Zhang D, O’Donnell M. 2016. The eukaryotic replication machine. Enzym. 39:191–229. doi:10.1016/bs.enz.2016.03.004.
   PubMedGoogle Scholar
• Johansson E, Macneill SA. 2010. The eukaryotic replicative DNA polymerases take shape. Trends Biochem Sci. 35:339–347. doi:10.1016/j.tibs.2010.01.004.
   PubMed Web of Science ®Google Scholar
• Irwin JJ Using ZINC to acquire a virtual screening library. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al] 2008; Chapter 14:Unit 14 6.
   Google Scholar
• Zhang P, Frugulhetti I, Jiang Y, Holt GL, Condit RC, Lee MY. Expression of the catalytic subunit of human DNA polymerase delta in mammalian cells using a vaccinia virus vector system. J Biol Chem. 1995;270:7993–7998.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhou Y, Lee EYC, Lee MYWT, Frick DN. 2010. The p12 subunit of human polymerase delta modulates the rate and fidelity of DNA synthesis. Biochemistry. 49:3545–3554. doi:10.1021/bi100042b.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhou Y, Zhang S, Lee EY, Frick DN, Lee MY. 2009. DNA damage alters DNA polymerase delta to a form that exhibits increased discrimination against modified template bases and mismatched primers. Nucleic Acids Res. 37:647–657. doi:10.1093/nar/gkn1000.
   PubMed Web of Science ®Google Scholar
• Lee M, Wang X, Zhang S, Zhang Z, Lee EYC. Regulation and modulation of human DNA polymerase delta activity and function. Genes. 2017;8(7):190.
   Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. 2015. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 36:422–439. doi:10.1016/j.tips.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al. 2014. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:852–861. doi:10.1016/S1470-2045(14)70228-1.
   PubMed Web of Science ®Google Scholar
• George Paul A, Sharma-Walia N, Kerur N, White C, Chandran B. 2010. Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi’s sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen. Cancer Res. 70:3697–3708. doi:10.1158/0008-5472.CAN-09-3934.
   PubMedGoogle Scholar
• Salic A, Mitchison TJ. 2008. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A. 105:2415–2420. doi:10.1073/pnas.0712168105.
   PubMed Web of Science ®Google Scholar
• Buck SB, Bradford J, Gee KR, Agnew BJ, Clarke ST, Salic A. 2008. Detection of S-phase cell cycle progression using 5-ethynyl-2’-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2’-deoxyuridine antibodies. Biotechniques. 44:927–929. doi:10.2144/000112812.
   PubMed Web of Science ®Google Scholar
• Schwab RA, Niedzwiedz W. Visualization of DNA replication in the vertebrate model system DT40 using the DNA fiber technique. J Visualized Experiments: JoVE. 2011;56:e3255.
   Google Scholar
• Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987;56:279–285.
   PubMed Web of Science ®Google Scholar
• Wong SJ, Myette MS, Wereley JP, Chitambar CR. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clinil Cancer Res. 1999;5:439–443.
   PubMed Web of Science ®Google Scholar
• Kuriyama I, Mizuno T, Fukudome K, Kuramochi K, Tsubaki K, Usui T, Imamoto N, Sakaguchi K, Sugawara F, Yoshida H, et al. 2008. Effect of dehydroaltenusin-C12 derivative, a selective DNA polymerase alpha inhibitor, on DNA replication in cultured cells. Molecules. 13:2948–2961. doi:10.3390/molecules13122948.
   PubMed Web of Science ®Google Scholar
• McBurney MW, Whitmore GF. Mechanism of growth inhibition by methotrexate. Cancer Res. 1975;35:586–590.
   PubMed Web of Science ®Google Scholar
• Mitchell EP. Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer. Oncology (Williston Park, NY). 2000;14:30–32.
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Vaitkevicius VK. 5-Fluorouracil in clinical cancer experience with 155 patients. Cancer Chem Rep. 1960;6:8–11.
   PubMedGoogle Scholar
• Gold GL, Hall TC, Shnider BJ, Selawry O, Colsky J, Owens AH, Jr., Dederick MM, Holland JF,Brindley CO, Jones R. A clinical study of 5-fluorouracil. Cancer Res. 1959;19:935–939.
   PubMed Web of Science ®Google Scholar
• Maloisel L, Fabre F, Gangloff S. 2008. DNA polymerase delta is preferentially recruited during homologous recombination to promote heteroduplex DNA extension. Mol Cell Biol. 28:1373–1382. doi:10.1128/MCB.01651-07.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Cavallo F, Brunet E, Jasin M. 2011. Homologous recombination assay for interstrand cross-link repair. Methods Mol Biol. 745:283–291. doi:10.1007/978-1-61779-129-1_16.
   PubMedGoogle Scholar
• Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M. 2006. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol. 409:524–540. doi:10.1016/S0076-6879(05)09031-2.
   PubMed Web of Science ®Google Scholar
• Ahrabi S, Sarkar S, Pfister SX, Pirovano G, Higgins GS, Porter ACG, Humphrey TC. 2016. A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Nucleic Acids Res. 44:5743–5757. doi:10.1093/nar/gkw326.
   PubMed Web of Science ®Google Scholar
• De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI. 2016. Ovarian cancer: status of homologous recombination pathway as a predictor of drug response. Crit Rev Oncol Hematol. 101:50–59. doi:10.1016/j.critrevonc.2016.02.014.
   PubMed Web of Science ®Google Scholar
• Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al. 2015. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clinil Cancer Res. 21:4257–4261. doi:10.1158/1078-0432.CCR-15-0887.
   PubMed Web of Science ®Google Scholar
• Meehan RS, Chen AP. 2016. New treatment option for ovarian cancer: PARP inhibitors. Gynecologic Onc Res Practice. 3:3. doi:10.1186/s40661-016-0024-7.
   PubMedGoogle Scholar
• Moore DC, Ringley JT, Patel J. Rucaparib: A Poly(ADP-Ribose) polymerase inhibitor for BRCA-mutated relapsed ovarian cancer. J Pharm Pract. 2017;30:897190017743131.
   PubMedGoogle Scholar
• Taylor KN, Eskander RN. 2017. PARP inhibitors in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2018;13:145–158.
   Web of Science ®Google Scholar
• Scott LJ. 2017. Niraparib: first global approval. Drugs. 77:1029–1034. doi:10.1007/s40265-017-0752-y.
   PubMed Web of Science ®Google Scholar
• Syed YY. 2017. Rucaparib: first global approval. Drugs. 77:585–592. doi:10.1007/s40265-017-0716-2.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. 2005. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 315:971–979. doi:10.1124/jpet.105.084145.
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HMW. 2010. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 13:1–14. doi:10.1007/s10456-009-9160-6.
   PubMed Web of Science ®Google Scholar
• Todd RC, Lippard SJ. 2009. Inhibition of transcription by platinum antitumor compounds. Metallomics: Integrated Biometal Science. 1:280–291. doi:10.1039/b907567d.
   PubMed Web of Science ®Google Scholar
• Sonohara Y, Iwai S, Kuraoka I. 2015. An in vitro method for detecting genetic toxicity based on inhibition of RNA synthesis by DNA lesions. Genes env. 37:8. doi:10.1186/s41021-015-0014-8.
   PubMed Web of Science ®Google Scholar
• Ward J, Kapadia K, Brush E, Salhanick SD. 2013. Amatoxin poisoning: case reports and review of current therapies. J Emerg Med. 44:116–121. doi:10.1016/j.jemermed.2012.02.020.
   PubMed Web of Science ®Google Scholar
• Allen B, Desai B, Lisenbee N. 2012. Amatoxin: A Review. ISRN Emerg Med. 2012:1–4. doi:10.5402/2012/190869.
   Google Scholar
• Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann gastroenterology. 2012;25:106–118.
   PubMedGoogle Scholar
• Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, D’Incalci M. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol. 1992;30:459–464.
   PubMed Web of Science ®Google Scholar
• Moreland NJ, Illand M, Kim YT, Paul J, Brown R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 1999;59:2102–2106.
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Moyer JD, Suffness M, Harrison SD Jr., Cysyk R, Hamilton TC, Plowman J. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res. 1994;54:724–729.
   PubMed Web of Science ®Google Scholar
• Sargent JM, Elgie AW, Williamson CJ, Taylor CG. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br J Cancer. 1996;74:1730–1733.
   PubMed Web of Science ®Google Scholar
• Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, D’Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst. 1991;83:1160–1164.
   PubMedGoogle Scholar
• Leeds JM, Mathews CK. Cell cycle-dependent effects on deoxyribonucleotide and DNA labeling by nucleoside precursors in mammalian cells. Mol Cell Biol. 1987;7:532–534.
   PubMed Web of Science ®Google Scholar
• Leeds JM, Slabaugh MB, Mathews CK. DNA precursor pools and ribonucleotide reductase activity: distribution between the nucleus and cytoplasm of mammalian cells. Mol Cell Biol. 1985;5:3443–3450.
   PubMed Web of Science ®Google Scholar
• Momparler RL. Biochemical pharmacology of cytosine arabinoside. Med Pediatr Oncol. 1982;10(Suppl 1):45–48.
   PubMedGoogle Scholar
• Perrino FW, Mekosh HL. Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha. J Biol Chem. 1992;267:23043–23051.
   PubMed Web of Science ®Google Scholar
• Dietlein F, Thelen L, Reinhardt HC. 2014. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends in Genetics: TIG. 30:326–339. doi:10.1016/j.tig.2014.06.003.
   PubMed Web of Science ®Google Scholar
• Prakash R, Zhang Y, Feng W, Jasin M. 2015. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 7:a016600. doi:10.1101/cshperspect.a016600.
   PubMed Web of Science ®Google Scholar
• Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Mol Genet. 1996;5 :1489-1494.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. 2010. Microsatellite instability in colorectal cancer. Gastroenterology. 138:2073–87 e3. doi:10.1053/j.gastro.2009.12.064.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. 2015. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5:1137–1154. doi:10.1158/2159-8290.CD-15-0714.
   PubMed Web of Science ®Google Scholar
• Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F. 2017. Niraparib in ovarian cancer: results to date and clinical potential. Ther Adv Med Oncol. 9:579–588. doi:10.1177/1758834017718775.
   PubMed Web of Science ®Google Scholar
• Chang L, Chang M, Chang HM, Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Applied Imm Chem Mol Morphology: AIMM. 2018;26:e15–e21.
   PubMed Web of Science ®Google Scholar
• First tissue-agnostic drug approval issued. Cancer Discov. 2017;7:656.
   Web of Science ®Google Scholar
• McVey M, Khodaverdian VY, Meyer D, Cerqueira PG, Heyer W-D. 2016. Eukaryotic DNA Polymerases in homologous recombination. Annu Rev Genet. 50:393–421. doi:10.1146/annurev-genet-120215-035243.
   PubMed Web of Science ®Google Scholar
• Longley MJ, Pierce AJ, Modrich P. DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem. 1997;272:10917–10921.
   PubMed Web of Science ®Google Scholar
• Swan MK, Johnson RE, Prakash L, Prakash S, Aggarwal AK. 2009. Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase delta. Nat Struct Mol Biol. 16:979–986. doi:10.1038/nsmb.1663.
   PubMed Web of Science ®Google Scholar
• Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 18:2714–2723. doi:10.1002/elps.1150181505.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, Case DA, Kuntz ID, Rizzo RC. 2015. DOCK 6: impact of new features and current docking performance. J Comput Chem. 36:1132–1156. doi:10.1002/jcc.23905.
   PubMed Web of Science ®Google Scholar
• Mezencev R, Matyunina LV, Wagner GT, McDonald JF. 2016. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther. 23:446–453. doi:10.1038/cgt.2016.71.
   PubMed Web of Science ®Google Scholar
• Coley HM. Development of drug-resistant models. Methods Mol Med. 2004;88:267–273.
   PubMedGoogle Scholar